Impact Biomedical (IBO) Net Income towards Common Stockholders (2022 - 2026)

Impact Biomedical's Net Income towards Common Stockholders history runs 5 years deep, the most recent figure standing at -$2.3 million for Q1 2026.

• Quarterly Net Income towards Common Stockholders fell 78.72% year-over-year to -$2.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$18.1 million (up 27.61% YoY) and the FY2024 annual result came in at -$24.8 million, down 471.26% from the prior year.
• Net Income towards Common Stockholders was -$2.3 million for Q1 2026 at Impact Biomedical, down from -$1.5 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $4.2 million in Q3 2024 and bottomed at -$27.1 million in Q4 2024.
• A 5-year average of -$3.6 million and a median of -$1.2 million in 2023 frame the typical range for Net Income towards Common Stockholders.
• Peak annual rise in Net Income towards Common Stockholders reached 465.49% in 2024, while the deepest fall reached 2094.33% in 2024.
• Impact Biomedical's Net Income towards Common Stockholders stood at -$3.4 million in 2022, then jumped by 63.27% to -$1.2 million in 2023, then tumbled by 2094.33% to -$27.1 million in 2024, then surged by 94.56% to -$1.5 million in 2025, then tumbled by 54.85% to -$2.3 million in 2026.
• Business Quant data shows IBO's Net Income towards Common Stockholders at -$2.3 million in Q1 2026, -$1.5 million in Q3 2025, and -$14.4 million in Q2 2025.